Catinazzo Thomas 4

What Happened

• Thomas Catinazzo, Chief Financial Officer of Relay Therapeutics (RLAY), reported open‑market sales and option exercises in early April 2026. On April 7 he sold 17,717 shares for a weighted average price of $13.01, totaling $230,498. On April 9 he exercised 1,800 option shares (cost $5.22/share) and the same day sold 1,800 shares at $15.00/share for $27,000. The filing also shows a separate derivative entry for 1,800 shares at $0.00.

Key Details

• Transaction dates: April 7, 2026 (sale of 17,717 shares); April 9, 2026 (option exercise and same‑day sale of 1,800 shares).
• Prices & totals: 17,717 shares sold at weighted avg $13.01 = $230,498 (executed across $12.42–$13.46 per footnote); exercised 1,800 shares at $5.22 = $9,396 cost; sold those 1,800 at $15.00 = $27,000 proceeds.
• Shares owned after transaction: Not specified in this Form 4.
• Notable footnotes: The large April 7 sale was effected under a Rule 10b5‑1 trading plan adopted Oct 30, 2025 (footnote F1). Footnote F2 lists the trade price range for the April 7 sale. Footnote F3 references 13,075 shares underlying RSUs; footnote F4 explains background on a 2020 option grant and vesting schedule.
• Timeliness: Form 4 was filed April 9, 2026 for transactions through April 7, 2026 — appears timely (no late filing indicated).

Context

• The April 9 activity is an exercise of options followed by an immediate sale of the underlying shares (often called a cashless or sell‑to‑cover pattern). The additional M‑coded entry at $0.00 likely reflects a derivative/settlement entry (commonly seen when shares are surrendered or withheld) but the filing does not explicitly state the purpose.
• Sales under a pre‑arranged 10b5‑1 plan are routine and are executed according to the plan’s terms; they do not by themselves indicate the insider’s view of the company.